Innocan Pharma says Mackie Research sales group issues Enterprise report on its potential clinical, licensing and commercial catalysts

Corporation () announced Thursday that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the company.

The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.

READ: InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes

In a statement, Innocan said Mackie Research analyst Toby Ma highlighted the Israeli company’s potential clinical, licensing and commercial catalysts:

Pre-clinical data of CLX-CBD loaded exosomes to treat COVID-19 is expected in 9 to 12 months. Innocan is looking to out-license CLX and the liposome product before Phase 1 trials. Its CBD-based consumer health products are expected to be launched in several international markets in the fourth quarter of 2020. The company is looking to sign more regional distribution agreements going forward.

The Enterprise report is based upon general comments with no ratings and should not be construed to be a research report, Innocan said.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham